89 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
, partially offset by higher non-clinical and internal laboratory costs of $0.4 million, an increase of $0.3 million in personnel related costs due … with accounting, legal, communication and consulting fees and a decrease of $0.3 million in facility costs, partially offset by an increase of $0.2
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
partially offset by an increase of $0.2 million in stock-based compensation expense associated with stock option grants made in 2021 and 2022.
General … and accounting services of $0.5 million partially offset by an increase of $0.1 million in stock-based compensation expense associated with stock option
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
in the OLE study partially offset by a decrease in clinical costs associated with the Phase 2 nomlabofusp trial discussed above.
General and administrative … offset by a decrease of $0.2 million in legal fees.
For the full year 2023, the Company reported a net loss of $36.9 million, or $0.84 per share
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
expense associated with stock option grants made in the second half of 2020 and thus far in 2021, partially offset by a decrease of $1.4 million … in professional fees primarily associated with accounting, legal and consulting fees partially offset by an increase of $0.8 million in stock-based
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
, an increase of $0.4 million in professional fees primarily associated with an increase in legal IP costs and consulting fees, partially offset by a decrease … to $17.0 million for the 9-month period ending September 30, 2022. A decrease of $3.2
million in clinical supply manufacturing costs was offset
8-K
EX-99.1
md6he2 pw
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
t196guf9ello0ikothdp
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.1
o8mzlbyf mby
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
oxhc lx45kl78rtjh
7 Nov 18
Zafgen Reports Third Quarter 2018 Operating and Financial Results
4:15pm
8-K
EX-99.1
6nrdkdhr59 t10qpo
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
5ypk7itxtno fx
8 May 18
Zafgen Reports First Quarter 2018 Operating and Financial Results
4:09pm
8-K
EX-99.1
hzzj2
7 Aug 18
Zafgen Reports Second Quarter 2018 Operating and Financial Results
4:21pm
8-K
EX-99.1
7454tliandru47qwjxu
11 Mar 19
Results of Operations and Financial Condition
4:12pm
DEFA14A
sppgblag r49ykoie9
19 Aug 20
Additional proxy soliciting materials
6:13am
DEFA14A
5r4fp0gg 7o518agt79l
18 May 20
Additional proxy soliciting materials
9:55pm